On Jan. 4, 2022, Pfizer announced that the U.S. government had committed to purchasing an additional 10 million treatment courses of its COVID-19 oral therapy, PAXLOVID (nirmatrelvir tablets and ritonavir tablets).

This commitment supplemented the 10 million treatment courses previously contracted by the U.S. Government, bringing the total amount of treatment courses to 20 million. Collectively, approximately 10 million PAXLOVID treatment courses had been accelerated for delivery by the end of June, with the remaining 10 million to follow by the end of September.